Targeting cancer cells with biotin-dendrimer conjugates

Eur J Med Chem. 2009 Feb;44(2):862-8. doi: 10.1016/j.ejmech.2008.04.021. Epub 2008 May 9.

Abstract

Star-burst dendrimers represent a superior carrier platform for targeted drug delivery. Partially acetylated generation 5 (G5) polyamidoamine (PAMAM) dendrimer was conjugated with the targeting moiety (biotin) and the imaging moiety (fluoresceinisothiocyanate, FITC), and the resulting dendrimer-biotin conjugate was characterized by (1)H NMR, UV-vis spectrum. As revealed by flow cytometry and confocal microscopy, the bifunctional conjugate (dendrimer-biotin-FITC) exhibited much higher cellular uptake into HeLa cells than the conjugate without biotin. The uptake was energy-dependent, dose-dependent, and could be effectively blocked by dendrimer-conjugated biotin. Our results indicated that the biocompatible biotin-dendrimer conjugate might be a promising nano-platform for cancer therapy and cancer diagnosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Biocompatible Materials / chemical synthesis
  • Biocompatible Materials / pharmacokinetics
  • Biotin*
  • Dendrimers / chemistry*
  • Dendrimers / pharmacokinetics
  • Drug Delivery Systems / methods*
  • Fluorescein-5-isothiocyanate*
  • HeLa Cells
  • Humans
  • Neoplasms / diagnosis
  • Neoplasms / therapy
  • Polyamines / chemistry
  • Polyamines / pharmacokinetics

Substances

  • Antineoplastic Agents
  • Biocompatible Materials
  • Dendrimers
  • PAMAM Starburst
  • Polyamines
  • Biotin
  • Fluorescein-5-isothiocyanate